There are multiple levers available to raise the ROI for R&D in therapeutics
Artificial intelligence systems are expected to transform industries, where large amounts of data are available for training, and the pharmaceutical industry is one of the few industries, where multi-modal data is abundant. The impact of the recent advances in AI on the pharmaceutical industry is expected to be immense at every level from lead generation to clinical trials management and to marketing.
This half- day workshop will help bridge this gap at the executive level starting from the vocabulary and anthe overview of the data requirements to the understanding of the near-term hardware roadmaps covering GPU and other emerging technologies.
Objectives of the workshop:
Benefits of the workshop:
Attendees will learn how to:
With the costs of pharmaceutical development skyrocketing, companies are looking for new ways to innovate, obtain insights, and cut R&D costs. The use of biomarkers can dramatically improve success rates for drug development, and genomics and multi-omics data are the next steps in precision medicine and effective drug discovery. However, current datasets are often lacking in information and may be inaccessible, numerous gaps exist that need to be filled, and this information needs to be transformed into formats that are useful for pharma companies. Work needs to be done to obtain the right genomic data, efficiently combine this data with phenotypic and peripheral health data, and properly analysing it to deliver value. Blockchain technology is a tool that can be used to effectively manage patient data, including genomic sequences, such that data siloes can be broken, interoperability and collaboration can be increased, and novel insights can be delivered to provide effective solutions. Here use cases will be introduced for the implementation of blockchain in a precision medicine ecosystem, and describe how both pharma and patients can benefit from gaining access to such data.
The next step for learning about blockchain is to understand how to budget, design, and implement a blockchain-powered platform into the R&D process. In this half-day workshop, we will investigate the components of blockchain structured as a secure database and network. After identifying the specific needs of an organization, we will explore the technological requirements and skillsets to choose and implement an appropriate blockchain platform. For example, what kind of nodes, security, and access mechanisms need to be in place? Finally, we will explore use cases of blockchain as a viable and secure choice for pharmaceutical companies.
Objectives of the workshop:
Benefits of the workshop:
R&D: Chief Scientific Officers, Heads of R&D, R&D Innovation, R&D Strategy. Knowledge & Data Management (Discovery, Clinical & Real-World Data), R&D Analytics, OMICs R&D
IT & DATA: Chief Information Officers, Chief Technology Officers, R&D IT, informatics, data science, data analysts, bioinformatics.
Director,Strategy- World Wide Research and Development
Michael is a Director of Strategy in Pfizer’s World Wide R&D organization. His group supports strategy and innovation in pharmaceutical development across all therapeutic areas. His current focus is expanding the role of Artificial Intelligence in drug discovery to increase productivity and identify new therapies to help patients.
Prior to Pfizer, Michael was a Strategy Consultant at Strategy& (a PWC company) and PA Consulting. He was also VP of technology at Phosplatin Therapeutics, a NYC biotech startup.
Michael lives in Brooklyn, and in his spare time enjoys helping entrepreneurs get their ideas to market; with several successful launches, from KickStarter to biotech IPOs. His own inventions include a kitchen gadget for SkyMall, a dual language eReader App, and several medical diagnostics and products.
He has an MBA from Columbia Business School, and MS in Biomedical Engineering from Boston University, and a BA in Biology from University of Michigan.
Global Head Technology, Architecture, Digital Drug Development
Senior Technologist and Enterprise Digital Architect, Pascal has more than 20 years of experience leading global IT organizations, building high performing teams, managing Enterprise Architecture teams, leading digital innovation and delivering complex large scale, global programs. He joined Novartis and the Pharma industry in 2013 and is in charge of the technology evolution of the Drug Development Information System. Passionate by the new technology and by the transformation of the healthcare industry, excited to deploy a mix of Digital, IT technology, semiconductor and pharmaceutical knowledge to drive the acceleration in eHealth and digital medicine, Pascal advocates for a Blockchain consortium to accelerate the adoption of this technology in the healthcare in the industry
Global Lead EWS Service Operations & Engineering
Marco is a senior Digital Solutions Architect and has been with Novartis since 2005. In this capacity, he is essentially responsible for exploring, engineering, and implementing new technologies such as Blockchain, IoT and API Management. For the last two years, he is focusing on Blockchain and exploring various use cases for Pharma. He began his career as a programmer in 1988 and held various positions of increasing responsibilities in software development, engineering, operations, service management and solution design.
Chief Scientific Officer
Project Shivom, UK
As an experienced Director in 2 early stage health tech companies, Natalie is skilled in operations, business development, investor relations and R&D. She holds a Ph.D. from the Faculty of Medicine at the University of Toronto, with a research focus on ophthalmology, inflammatory disease, diagnostics and precision medicine. She is also the Healthcare Lead for the Government Blockchain Association European Strategic Conference. Natalie further combines a breadth of experience with 8+ years of teaching at University of Toronto & Trent University in Canada, and holding multiple board, management & consulting roles in the non-profit sector.
Co-founder, Insilico Medicine
CSO, The Biogerontology Research Foundation, USA
Alex Zhavoronkov, PhD, is the CEO of Insilico Medicine, Inc (Baltimore, MD) and the CSO of the Biogerontology Research Foundation (Oxford, UK). The company is focusing on applying deep learning and advanced signaling pathway activation analysis to biomarker discovery, drug discovery and drug repurposing for aging and age-related diseases. He is the author of over 70 research papers and books including” The Ageless Generation: How advances in biomedicine will transform the global economy” (Palgrave Macmillan, 2013). Prior to switching his focus to aging research in 2004, he served as the director of Central and Eastern Europe at ATI Technologies, publicly-traded GPU company and the Chief Thought Architect at NeuroG, a neuroinformatics company. He holds two Bachelor degrees from Queen’ s University, a Masters in biotechnology from Johns Hopkins University, and a PhD in biophysics from the Moscow State University.
Head of Business Development
Ashley Kemball-Cook is Head of Business Development for Qadre, a
blockchain product development company with products in a number of
sectors including: supply chain management, anti-counterfeiting, and
identity. Ashley is an Advisor to Disberse, a blockchain enabled fund
management platform for humanitarian aid. Using blockchain it drives the transparent, efficient, and effective flow of humanitarian aid funds.
Ashley has worked on blockchain projects with industry leaders across
finance, energy, healthcare, Magic Circle Law Firms, and UK regulators.
Ashley also has experience in consulting across a range of applications of blockchain in pharmaceuticals, including: internal remittance and clearing, fertility tracking, empowerment of patients, streamlining interactions with regulators, streamlining clinical trials, sharing of certain clinical trials information, and integration with IoT devices to ensure medicine is kept at specific temperatures.
Business and Legal Associate
Lucie Munier is a Law graduate with experience working across Asia in the High Growth Technology and Innovation Group within KPMG. Lucie has also worked within high growth companies in cybersecurity and corporate advisory in Geneva before moving to London to join Qadre as Legal and Business Associate. Lucie combines her experience in cybersecurity and law and passion for high growth innovation to lead Qadre’s work on regulation and Business Development.
Genomics Data Engineer
Frank Austin Nothaft is a Genomics Data Engineer at Databricks and a PhD candidate in Computer Science at UC Berkeley. Frank is one of the core developers on the ADAM/Big Data Genomics project, pioneering methods for processing large genomics datasets using Apache Spark. Frank holds a Masters of Science in Computer Science from UC Berkeley, and a Bachelors of Science with Honors in Electrical Engineering from Stanford University. Prior to joining UC Berkeley, Frank worked at Broadcom Corporation on design automation techniques for industrial scale wireless communication chips.